Major Depressive Disorder Clinical Trial
Official title:
Adolescent Depression Treatment Pathways in Primary Care - a Longitudinal Cohort Study Describing Naturalistic Flow of Treatment and Evaluating Effectiveness and Cost-effectiveness of Interpersonal Counseling Compared to Treatment as Usual
The demand for prevention and treatment of adolescent depression has rapidly increased over years. A national project to improve treatment of adolescent depression in primary care has taken place in Finland starting 2020. The goal of this prospective observational cohort study is to describe pathways to mental health services in adolescents with depressive symptoms. The main questions it aims to answer are: - Do young people reporting depressive symptoms have equal access to treatment? - How is it best to recognize those adolescents who will benefit from IPC-A? Adolescents who participate in the study will - complete a survey on protective and risk factors of depression three times over 6 months - report possible depressive symptoms every two weeks over 6 months - report whether they needed and received help, motivation for treatment, and benefits and harms from treatment We will also collect - information from one of caretakers with two surveys within 6 month- intervals on their view on adolescent's need for support, strengths and risks, and benefits and harms from treatment where applicable - where applicable, from the professional who provided support after the intervention on their training and competence, as well as content of and response to treatment - register data to estimate overall provision and cost of social welfare and health care services one year preceding the study and over 2 to 10 years after the observation period Researchers will compare an intervention that is new in Finland, adolescent interpersonal counseling (IPC-A), to other treatments of depression, to see if it is equal to or better than other treatments of depression.
Status | Recruiting |
Enrollment | 9000 |
Est. completion date | December 2039 |
Est. primary completion date | May 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 13 Years to 16 Years |
Eligibility | Inclusion Criteria: - we will include all adolescents attending grades 7 to 9 in selected schools with on informed consent Exclusion Criteria: - psychiatric care within the past 12 months or receiving a psychosocial intervention (psychotherapy, IPC-A, any other therapy of support) during the 12 months before baseline, - an inability to reliably understand the Finnish, Plain Finnish, Swedish, or English versions of the survey, or - an adolescents' or caretakers' report of a need for exclusion, such as another medical condition - including a mental disorder - requiring acute current treatment or support. |
Country | Name | City | State |
---|---|---|---|
Finland | The wellbeing services county of Kanta-Häme | Hämeenlinna | |
Finland | Finnish Institute for Health and Welfare | Helsinki | |
Finland | The wellbeing services county of Central Finland | Jyväskylä | |
Finland | The wellbeing services county of North Ostrobothnia | Oulu |
Lead Sponsor | Collaborator |
---|---|
Finnish Institute for Health and Welfare | Strategic Research Council of Finland, Tampere University, University of Eastern Finland, University of Helsinki |
Finland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Loneliness | One item: Do you feel lonely? yes/no | No time frame | |
Other | Experiences of Social Inclusion Scale | 10 items, 0 to 4, higher score more inclusion | No time frame | |
Other | The child-friendly EuroQol-5 dimensions questionnaire | EQ-5D-Y, 5 items 0 to 2; a VAS scale, higher score more functional | The same day | |
Other | Generalized Anxiety Disorder Scale-7 | GAD-7, 7 items 0 to 3, higher score more anxiety | 2 weeks | |
Other | The Short Warwick-Edinburg Mental Wellbeing Scale | SWEMWBS, 7 items for positive mental health 0 to 4, higher score more positive mental health | 2 weeks | |
Other | Young Person's Clinical Outcomes in Routine Evaluation-Outcome Measure | YP-CORE; 10 items 0 to 4, higher score better outcome | 1 week | |
Other | 3x10D life situation assessment tool | 3x10-Dx, 10 items 0 to 0, higher score better life situation | No time frame | |
Other | Harmful behavior: Alcohol and substance use, self-harming behavior | Questions yes/no, open field | Ever, past 30 days | |
Primary | Proportion of adolescents referred to specialized psychiatric services | Proportion of adolescents in each three groups with sustained depressive symptoms by 6 months who receive specialized psychiatric services by 12 months | From baseline to 12 months | |
Secondary | Proportion of adolescents who received any social welfare or health care services | Data collected from adolescent and caretaker's surveys and registers | Up to 10 years after baseline | |
Secondary | longitudinal changes in PHQ-9-A score | Longitudinal changes in biweekly PHQ-9-A scores over 6 months; PHQ-9-A 10 items, 0 to 3, higher score more depression | 2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |